Author

U. Keller

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Assay:electronic health records· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

G. Schneider· 2 shared M. Reichert· 2 shared M. Wirth· 2 shared A. Baluapuri· 1 shared A. Elting· 1 shared A. Illendula· 1 shared A. Janning· 1 shared A. T. den Dekker· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

G. Schneider

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Tetraspanner-based nanodomains modulate BAR domain-induced membrane curvature

D. Haase, C. Rasch, U. Keller, A. Elting, J. Wittmar, A. Janning, M. Kahms, C. Schuberth, J. Klingauf, R. Wedlich-Soldner

The paper investigates the opposing roles of Sur7 and Nce102 tetraspanner proteins in modulating membrane curvature and domain topography in yeast.

bioRxiv · Nov 21, 2022Cell Biology

NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer

J. Doffo, S. A. Bamopoulos, H. Kose, F. Orben, M. Pons, A. T. den Dekker, R. W. W. Brouwer, A. Baluapuri, S. Habringer, M. Reichert, A. Illendula, O. H. Kramer, M. Schick, E. Wolf, W. F. J. van IJcken, , M. Wirth

The paper identifies RUNX1 inhibition as a strategy to induce NOXA-dependent apoptosis in pancreatic cancer, showing it blocks tumor growth in vivo and in organoids.

bioRxiv · Oct 21, 2021Cancer Biology

Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC

K. Lankes, Z. Hassan, M. J. Doffo, C. Schneeweis, S. Lier, R. Oellinger, R. Rad, O. H. Kraemer, U. Keller, D. Saur, M. Reichert, G. Schneider, M. Wirth

The paper identifies bortezomib as a potential therapy for MYC hyperactive pancreatic cancer by showing its sensitivity to proteasome inhibition.

bioRxiv · Jul 1, 2020Cancer Biology